Your session is about to expire
← Back to Search
ZN-d5 for AL Amyloidosis
Study Summary
This trial is testing a new drug for people with a specific type of blood cancer that has come back or doesn't respond to treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I do not have heart failure or irregular heartbeats.I have had 1 to 3 treatments for AL amyloidosis.My bone marrow is functioning well enough for treatment.My condition is non-AL amyloidosis, including wild-type or mutated ATTR.It's been over 3 months since my last major treatment or enough time for previous drugs to leave my system.My organs have been affected by my condition.I have been treated with BCL-2 inhibitors before.My cancer has been tested for the t(11,14) genetic change.I can take care of myself but might not be able to do heavy physical work.I have been diagnosed with AL amyloidosis through tissue testing.My organs are working well.My condition is classified as Stage IV according to Mayo 2012.I have been diagnosed with multiple myeloma.Your disease can be measured using a specific blood test for light chain proteins.
- Group 1: Treatment Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many medical sites are currently executing this clinical experiment?
"Currently, 4 sites are running this clinical trial. These include locations in New Orleans, Nashville and Denver alongside an additional 4 cities. To keep travel to a minimum, it is advised that participants select the site closest to them for enrollment."
What goals are researchers striving to achieve by conducting this investigation?
"The primary outcome of this 18 month trial is to evaluate the safety and tolerability. Additionally, researchers will assess hematologic response to ZN-d5 by quantifying complete responses (CR), very good partial responses (VGPR), partial responses (PR) or no response/progressive disease (NR/PD). Duration and time to a CR+VGPR or mCR+ VGPR must also be recorded while measuring half life of ZN-d5 in plasma samples from different dose levels."
Is recruitment for this medical experiment still ongoing?
"Per the clinicaltrials.gov entry, this scientific experiment is still seeking participants as of October 4th 2022 - having initially been posted on November 30th 2021."
What is the upper limit of participants for this research study?
"This study necessitates 135 participants meeting its inclusion criteria, with enrolment being conducted at sites such as Site 0200 in New Orleans and Site 0199 in Nashville."
Share this study with friends
Copy Link
Messenger